Flag of the European Union EU Clinical Trials Register Help

Clinical trials for lenalidomide

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   35359   clinical trials with a EudraCT protocol, of which   5786   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    278 result(s) found for: lenalidomide. Displaying page 1 of 14.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-019173-16 Sponsor Protocol Number: MM5 Start Date*: 2010-07-08
    Sponsor Name:University Hospital Heidelberg
    Full Title: Randomised phase III trial for previously untreated multiple myeloma to evaluate two regimens of bortezomib based induction therapy and lenalidomide consolidation followed by lenalidomide maintenan...
    Medical condition: multiple myeloma (symptomatic, newly diagnosed)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000555-10 Sponsor Protocol Number: HO147 Start Date*: 2018-06-21
    Sponsor Name:HOVON Foundation
    Full Title: Carfilzomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma: A Randomized Phase II Study.
    Medical condition: Smoldering multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10075894 Smoldering myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003079-40 Sponsor Protocol Number: GMMG-HD6 Start Date*: 2015-06-16
    Sponsor Name:Ruprecht-Karls-University Heidelberg, Medical Faculty represented by University Hospital Heidelberg
    Full Title: A randomized phase III trial on the effect of elotuzumab in VRD induction /consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma
    Medical condition: Newly diagnosed symptomatic multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005804-16 Sponsor Protocol Number: 1256803 Start Date*: 2013-05-24
    Sponsor Name:CHU de Toulouse
    Full Title: Front-line therapy with Carfilzomib, Lenalidomide, and Dexamethasone (CRd) induction followed by autologous stem cell transplantation, CRd consolidation and Lenalidomide maintenance in Newly Diagn...
    Medical condition: Multiple Myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002146-72 Sponsor Protocol Number: CC-5013-AML-002 Start Date*: 2017-07-03
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (REVLIMID®) in Pediatric Subjects from 1 to ≤ 18 Years of Age with Relapse...
    Medical condition: Leukemia, Myeloid
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000012984 10000886 Acute myeloid leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2008-004083-39 Sponsor Protocol Number: DSMM_XIII Start Date*: 2009-10-19
    Sponsor Name:GMIHO Gesellschaft für Medizinische Innovation – Hämatologie und Onkologie mbH
    Full Title: The combination of Lenalidomide and Dexamethasone with or without intensification by high-dose Melphalan in the treatment of multiple myeloma
    Medical condition: primary treatment of multiple myeloma patients of age 60 till 75 years
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001616-11 Sponsor Protocol Number: DSMM_XVII Start Date*: 2018-06-25
    Sponsor Name:University Hospital Wuerzburg
    Full Title: Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma and Subs...
    Medical condition: Newly Diagnosed Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001639-21 Sponsor Protocol Number: NMDSG10B Start Date*: 2011-11-01
    Sponsor Name:NMDSG Nordics Myeloplastics Syndrom Study Group
    Full Title: A multicentre open randomized phase II study of the efficacy and safety of azacitidine alone or in combination with lenalidomide in high-risk myeloid disease (high-risk MDS and AML) with a karyotyp...
    Medical condition: Myelodysplastic syndrome and acute myeloid leukemia with a deletion of 5q
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067096 5q minus myelodysplastic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing) FI (Completed) NO (Ongoing) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001355-76 Sponsor Protocol Number: UCL/13/0291 Start Date*: 2016-05-09
    Sponsor Name:University College London
    Full Title: Phase III randomised trial of immunomodulatory therapy in high risk solitary bone plasmacytoma
    Medical condition: Solitary bone plasmacytoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035484 Plasmacytoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002380-42 Sponsor Protocol Number: CRdvsR Start Date*: 2016-10-31
    Sponsor Name:Polish Myeloma Consortium
    Full Title: Phase 3 Randomized trial of carfilzomib, lenalidomide, dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma.
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000547-34 Sponsor Protocol Number: QoL-ESC RevMDS Start Date*: 2008-06-09
    Sponsor Name:ASSOCIAZIONE QOL-ONE
    Full Title: Lenalidomide for Myelodysplastic Syndromes: Efficacy, Safety, Cardiac Changes, and Quality of Life (QoL-ESC RevMDS)
    Medical condition: Low or Intermediate-1 IPSS risk MDS with del(5q)as a single or combined cytogenetic abnormality and with anemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005329 Blood and lymphatic system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003168-35 Sponsor Protocol Number: IELSG-40 Start Date*: 2016-08-31
    Sponsor Name:IELSG International Extranodale Lymphoma Study Group; Instituto Oncologico della Svizzera Italiana,
    Full Title: A phase II trial addressing feasibility and activity of clarithromycin + lenalidomide combination: a full oral treatment for patients with relapsed/refractory extranodal marginal zone lymphoma
    Medical condition: extranodal marginal zone lymphoma (MALT)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004768-37 Sponsor Protocol Number: GMMG-HD7 Start Date*: 2018-10-11
    Sponsor Name:Ruprecht-Karls-University Heidelberg, Medical Faculity, represented by University Hospital Heidelberg
    Full Title: A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) induction and lenalidomide maintenance in patients with newly dia...
    Medical condition: Newly diagnosed symptomatic multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000665-36 Sponsor Protocol Number: 20180015 Start Date*: 2019-05-09
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Open-label, Phase 3 Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination with Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma...
    Medical condition: Relapsed or Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) ES (Ongoing) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001051-39 Sponsor Protocol Number: FMG-MM-02 Start Date*: 2012-11-15
    Sponsor Name:Kuopio University Hospital, Clinic of Internal Medicine/Center of Medicine
    Full Title: A prospective phase II study to assess immunophenotypic remission after three-drug in-duction followed by randomized stem cell mobilization, autologous stem cell transplantation and lenalidomide ma...
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004007-34 Sponsor Protocol Number: HOVON87MM/NMSG18 Start Date*: 2008-11-20
    Sponsor Name:HOVON Foundation
    Full Title: Randomized phase III trial in elderly patients with previously untreated symptomatic Multiple Myeloma comparing MP-Thalidomide (MP-Thal) followed by thalidomide maintenance versus MP-Lenalidomide (...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) SE (Ongoing) DK (Ongoing) BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016616-21 Sponsor Protocol Number: DSMMXIV Start Date*: 2011-10-20
    Sponsor Name:Wuerzburg University Hospital
    Full Title: Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma followed by Response-adapted Consolidation and ...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004469-32 Sponsor Protocol Number: CC-5013-CLL-001 Start Date*: 2007-02-23
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 1/2, MULTI-CENTER,OPEN LABEL STUDY OF THE SAFETY AND EFFICACY OF A STEPWISE DOSE-ESCALATION SCHEDULE OF LENALIDOMIDE MONOTHERAPY IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL CHRONIC LYMP...
    Medical condition: For the treatment of relapsed or refractory B-CLL.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003946 B-Lymphocytic, CLL (Kiel Classification) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FR (Ongoing) GB (Temporarily Halted) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001620-29 Sponsor Protocol Number: R2-GDP-GOTEL Start Date*: 2014-10-19
    Sponsor Name:Grupo Español para el Tratamiento y Estudio de los Linfomas (GOTEL)
    Full Title: Phase II clinical trial to evaluate the combination of lenalidomide with R-GDP (rituximab, gemcitabine, dexamethasone and cisplatin) in patients diagnosed with refractory diffuse large B-cell lymph...
    Medical condition: Refractory Diffuse large B-cell lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001430-27 Sponsor Protocol Number: CLL-5 Start Date*: 2008-08-28
    Sponsor Name:Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
    Full Title: Fludarabine/Rituximab combined with escalating doses of Lenalidomide followed by Rituximab/Lenalidomide in untreated chronic lymphocytic leukemia (CLL) – a dose-finding study with concomitant evalu...
    Medical condition: Untreated chronic lymphocytic leukaemia (B-CLL)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003946 B-Lymphocytic, CLL (Kiel Classification) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2019 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA